Topical Ganciclovir Versus Systemic Aciclovir in the Treatment of Herpetic Keratitis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Corneal healing
研究概览
简要总结
Traditional antiviral treatments, including systemic acyclovir, have shown effectiveness in resolving keratitis but can also lead to complications, including ocular surface toxicity and the development of acyclovir-resistant strains of HSV. Topical ganciclovir 0.15% ophthalmic gel presents a safer alternative for managing herpetic keratitis, offering effective viral suppression with minimal toxicity. This study aims to compare the efficacy and safety of topical ganciclovir versus systemic acyclovir in treating herpetic keratitis, providing valuable insights into optimal management strategies for this condition
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with herpetic keratitis
排除标准
- •Patients with known allergies to ganciclovir or acyclovir
- •Severe ocular surface disease
- •Those who have previously received antiviral therapy for herpetic keratitis within the last month
研究组 & 干预措施
ganciclovir
干预措施: Ganciclovir (GCV) (Drug)
Systemic acyclovir
干预措施: Acyclovir 400 MG (Drug)
结局指标
主要结局
Corneal healing
时间窗: At 4 and 6 weeks
Heling of the keratitis
次要结局
- Sie effects(at 4 and 6 weeks)
研究者
Ehab Tharwat
Principal Investigator
Al-Azhar University